<unk> , sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains<unk> , a programmed death receptor-1 (PD-1) blocking antibody, and<unk> , a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022.
Nivolumab/relatlimab
Enfortumab vedotin
Bamlanivimab/etesevimab
Loncastuximab tesirine
Sacituzumab govitecan
Moxetumomab pasudotox
Tisotumab vedotin
Pembrolizumab